DEFA14A: Aethlon Medical Amends Warrants, Shares Immediately Exercisable

Aethlon Medical, Inc. announced amendments to its Pre-Funded Warrants, making them immediately exercisable, while still seeking shareholder approval for Nasdaq compliance.

Summary

• Aethlon Medical, Inc. issued a supplement to its proxy statement for the Annual Meeting of Stockholders scheduled for February 19, 2026.
• On January 22, 2026, the company entered into an Amendment to the Pre-Funded Common Stock Purchase Warrants (PFW Amendment) and an Amendment to the Securities Purchase Agreement (SPA Amendment).
• These amendments removed the contractual requirement that the Pre-Funded Warrants be exercisable only following receipt of stockholder approval.
• As a result, the Pre-Funded Warrants are now exercisable immediately, subject to their terms and conditions, including applicable beneficial ownership limitations.
• The company continues to seek stockholder approval under Proposal No. 5 for purposes of complying with Nasdaq Listing Rule 5635(d), concerning the issuance of up to an aggregate of 1,662,553 shares of Common Stock from various warrants.
• Regardless of the outcome of Proposal No. 5, the company may issue shares of Common Stock upon exercise of the Pre-Funded Warrants.
• Stockholder approval remains required for the Common Warrants and the Placement Agent Warrants, and the shares of Common Stock issuable upon their exercise.
• The Board of Directors continues to recommend that stockholders vote FOR Proposal No. 5.

Sentiment

Score: 6

Explanation: The immediate exercisability of Pre-Funded Warrants is a positive for the company's financing flexibility and for warrant holders. However, the removal of a shareholder approval condition for these specific warrants could be viewed negatively from a corporate governance perspective, even if approval is still sought for Nasdaq compliance. It's a mixed bag, leaning slightly positive due to operational streamlining.

Positives

• Pre-Funded Warrants are now immediately exercisable, potentially providing earlier access to capital for the company or reducing uncertainty for warrant holders.
• The company is actively working to comply with Nasdaq listing rules, which is a positive for maintaining its listing status.

Negatives

• The removal of the contractual requirement for stockholder approval for Pre-Funded Warrants' exercisability effectively bypasses direct shareholder consent on this specific condition, which could be viewed as a corporate governance concern.
• The need for amendments to the Securities Purchase Agreement and Pre-Funded Warrants suggests initial terms may have required adjustment or were not fully optimized.

Risks

• Potential for shareholder dissatisfaction or perception of reduced corporate governance due to the removal of the stockholder approval condition for Pre-Funded Warrants.
• Risk of dilution from the issuance of up to 1,662,553 shares upon warrant exercise, particularly from Pre-Funded Warrants which can now be exercised regardless of the vote on Proposal No. 5.
• Failure to obtain stockholder approval for the Common Warrants and Placement Agent Warrants could impact future financing flexibility or Nasdaq compliance for those specific instruments.

Future Outlook

The company intends to issue shares of Common Stock upon exercise of the Pre-Funded Warrants immediately, regardless of the outcome of Proposal No. 5. It continues to seek stockholder approval for Nasdaq compliance for all warrants under Proposal No. 5.

Management Comments

• The Board of Directors continues to recommend that stockholders vote FOR Proposal No. 5.

Industry Context

This type of amendment is common when companies need to adjust financing terms to meet regulatory requirements or facilitate earlier access to capital, particularly in sectors like biotech or medical devices where funding is critical. The immediate exercisability of warrants can be seen as a move to streamline capital infusion or provide certainty to investors.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution from warrant exercises, especially Pre-Funded Warrants which can now be exercised without prior shareholder approval. The vote on Proposal No. 5 still impacts other warrants and Nasdaq compliance.
• Warrant Holders: Pre-Funded Warrant holders benefit from immediate exercisability, removing a condition precedent.
• Nasdaq: The company is actively seeking to comply with Nasdaq Listing Rule 5635(d).

Next Steps

• The Annual Meeting of Stockholders will be held on February 19, 2026, where Proposal No. 5 will be voted upon.
• Shareholders may revoke or change their proxy votes before the Annual Meeting.
• The company may issue shares of Common Stock upon exercise of Pre-Funded Warrants immediately.
• Stockholder approval is still required for Common Warrants and Placement Agent Warrants.

Key Dates

Recommendation

The filing clarifies a technical aspect of a previous financing, streamlining warrant exercise. While this provides certainty and potentially faster capital for the company, it also highlights potential dilution without direct shareholder approval for a portion of the warrants. This creates a mixed signal. A seasoned investor would likely hold to observe the market's reaction to the accelerated exercisability and the broader implications for the company's capital structure and shareholder relations, rather than making an immediate buy or sell decision based solely on this procedural update.

Keywords

Aethlon Medical, Warrants, Pre-Funded Warrants, Nasdaq Listing Rule 5635(d), Shareholder Approval, Private Placement, PIPE, Common Stock, Corporate Governance, Dilution, Proxy Statement Supplement